Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional Results available

Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

ClinicalTrials.gov ID: NCT02957682

Public ClinicalTrials.gov record NCT02957682. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Praluent on Neurocognitive Function in Patients With Heterozygous Familial Hypercholesterolemia or With Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main purpose of this study is to evaluate the effect on mental state (known as "neurocognitive function") with use of Praluent.

Study identification

NCT ID
NCT02957682
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Regeneron Pharmaceuticals
Industry
Enrollment
2,176 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
40 Years to 85 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 2, 2016 (Actual)
Primary completion
Mar 5, 2020 (Actual)
Completion
Mar 5, 2020 (Actual)
Last update posted
May 7, 2021

2016 – 2020

United States locations

U.S. sites
73
U.S. states
26
U.S. cities
66
Facility City State ZIP Site status
Regeneron Study Site Auburn Alabama 36830 —
Regeneron Study Site Birmingham Alabama 35209 —
Regeneron Study Site Mobile Alabama 36608 —
Regeneron Study Site Beverly Hills California 90210 —
Regeneron Study Site Los Gatos California 95032 —
Regeneron Study Site North Hollywood California 91606 —
Regeneron Study Site Port Hueneme California 93041 —
Regeneron Study Site Westminster California 92683 —
Regeneron Study Site 1 Aurora Colorado 80012 —
Regeneron Study Site 2 Aurora Colorado 80012 —
Regeneron Study Site Colorado Springs Colorado 80906 —
Regeneron Study Site Lake Worth Florida 33461 —
Regeneron Study Site Lake Worth Florida 33462 —
Regeneron Study Site Miami Springs Florida 33166 —
Regeneron Study Site Covington Georgia 30014 —
Regeneron Study Site Champaign Illinois 61822 —
Regeneron Study Site Chicago Illinois 60602 —
Regeneron Study Site Chicago Illinois 60640 —
Regeneron Study Site Rock Island Illinois 61201 —
Regeneron Study Site Evansville Indiana 47714 —
Regeneron Study Site Indianapolis Indiana 46237 —
Regeneron Study Site Ames Iowa 50010-3014 —
Regeneron Study Site Iowa City Iowa 52242 —
Regeneron Study Site Waterloo Iowa 50702 —
Regeneron Study Site Hutchinson Kansas 67502 —
Regeneron Study Site Newton Kansas 67114 —
Regeneron Study Site Overland Park Kansas 66209 —
Regeneron Study Site Louisville Kentucky 40213 —
Regeneron Study Site Bangor Maine 04401 —
Regeneron Study Site Baltimore Maryland 21229 —
Regeneron Study Site Oxon Hill Maryland 20745 —
Regeneron Study Site Minneapolis Minnesota 55407 —
Regeneron Study Site Olive Branch Mississippi 38654 —
Regeneron Study Site Washington Missouri 63090 —
Regeneron Study Site Buffalo New York 14215 —
Regeneron Study Site New Hyde Park New York 11042 —
Regeneron Study Site Cary North Carolina 27518 —
Regeneron Study Site Charlotte North Carolina 28209 —
Regeneron Study Site Charlotte North Carolina 28277 —
Regeneron Study Site Greensboro North Carolina 27401 —
Regeneron Study Site Hickory North Carolina 28601 —
Regeneron Study Site High Point North Carolina 27262 —
Regeneron Study Site Raleigh North Carolina 27609 —
Regeneron Study Site Rocky Mount North Carolina 27804 —
Regeneron Study Site Salisbury North Carolina 28144 —
Regeneron Study Site Statesville North Carolina 28625 —
Regeneron Study Site Wilmington North Carolina 28401 —
Regeneron Study Site Winston-Salem North Carolina 27103 —
Regeneron Study Site Cincinnati Ohio 45219 —
Regeneron Study Site Cleveland Ohio 44122 —
Regeneron Study Site Dayton Ohio 45414 —
Regeneron Study Site Duncansville Pennsylvania 16635 —
Regeneron Study Site Charleston South Carolina 29407 —
Regeneron Study Site Greenville South Carolina 29485 —
Regeneron Study Site Summerville South Carolina 29615 —
Regeneron Study Site Rapid City South Dakota 57701 —
Regeneron Study Site Bristol Tennessee 37620 —
Regeneron Study Site Knoxville Tennessee 37760 —
Regeneron Study Site Knoxville Tennessee 37912 —
Regeneron Study Site Knoxville Tennessee 37938 —
Regeneron Study Site Powell Tennessee 37849 —
Regeneron Study Site Dallas Texas 75231 —
Regeneron Study Site Houston Texas 77002 —
Regeneron Study Site Houston Texas 77027 —
Regeneron Study Site Schertz Texas 78154 —
Regeneron Study Site Shavano Park Texas 78231 —
Regeneron Study Site Falls Church Virginia 22601 —
Regeneron Study Site Winchester Virginia 22042 —
Regeneron Study Site Burien Washington 98166 —
Regeneron Study Site Everett Washington 98405 —
Regeneron Study Site Tacoma Washington 98405 —
Regeneron Study Site Walla Walla Washington 99362 —
Regeneron Study Site Manitowoc Wisconsin 54220 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 115 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02957682, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 7, 2021 · Synced Oct 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02957682 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →